KIRKLAND, QC, April 26 /CNW Telbec/ - Today, Merck announced that Health
Canada has extended the indication of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18)
Recombinant Vaccine] in women up to the age of 45. Merck's HPV vaccine
is now approved for girls and women nine through 45 years of age for
the prevention of cervical cancer, vulvar and vaginal cancers,
precancerous lesions and genital warts caused by the Human
Papillomavirus (HPV) types 6, 11, 16, 18. Previously, GARDASIL® was approved in girls and women nine through 26.
"The decision to be vaccinated against HPV-related diseases as an adult
should be taken by each individual woman in consultation with her
healthcare professional," said Dr. Vivien Brown, a family physician on
staff at Mount Sinai Hospital, the University Health Network and North
York General Hospital. "The HPV quadrivalent vaccine is not only for
young people, both girls and boys, who have not yet been exposed to
HPV, it's also effective in older women."
"Whatever the reason, there's a tendency for women to remain at risk of
acquiring new HPV infections as they get older. Whether they are
changing their social status or not, women should talk to their doctors
about the HPV protection provided by the quadrivalent vaccine," said
Dr. Alex Ferenczy, Professor of Pathology and Obstetrics & Gynecology
at McGill University. "Evidence based medicine now suggests that
physicians may propose the HPV quadrivalent vaccine to female patients
up to age 45, on an individual basis."
GARDASIL® was also approved in February 2010 for boys and men nine through 26
years of age for the prevention of infection caused by HPV types 6, 11,
16, and 18 and genital warts caused by HPV types 6 and 11.
Efficacy in women up to age 45
GARDASIL® was evaluated in a placebo-controlled, double-blind, randomized
efficacy study (FUTURE III) conducted in 3,817 women aged 24 to 45
years. The primary analysis was conducted in the per protocol efficacy
(PPE) population which consisted of individuals who received all three
vaccinations within one year of enrolment, did not have any major
deviations from the study protocol, and who were naïve to HPV types 6,
11, 16 and 18 when they started the study and remained free of
infection to these four HPV types through one month after receiving
their last vaccine dose.
The efficacy of GARDASIL® against the combined incidence of HPV 6-, 11-, 16- or 18-related
persistent infection, genital warts, vulvar and vaginal lesions, CIN of
any grade and AIS-the immediate precursors to cervical cancer and
cervical adenocarcinoma-and cervical cancers was 88.7% (95% CI: 78.1,
The most common systemic adverse reaction observed was headache. Other
common adverse reactions that were observed among recipients of
GARDASIL® at a frequency of at least 1.0 percent and greater than placebo were:
fever, nausea, dizziness, injection-site pain, swelling, redness or
itching of the skin and bruising.
At high risk up to age 45
Women are at high risk for diseases caused by HPV types 6, 11, 16 and 18
up to the age of 45.1 The lifetime risk for acquiring genital warts-highest for both men and
women between the ages of 15 and 34-has been estimated to exceed 10%.2
In a Canadian study published in 2009 in the journal, Sexually
Transmitted Diseases, more than half (56 per cent) of individuals in a
new sexual relationship were infected by HPV.3 Each year in Canada HPV infections lead to approximately 350,000
abnormal Pap smear results4, 41,450 new cases of genital warts5, 1,350 cervical cancer diagnoses and 400 cervical cancer deaths.6 After breast cancer, cervical cancer is the most common cancer in
Canadian women between the ages of 20 and 44.7
Today's Merck is a global healthcare leader working to help the world be
well. Merck is known as MSD outside the United States and Canada.
Through our medicines, vaccines, biologic therapies, and consumer and
animal products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate
our commitment to increasing access to healthcare through far-reaching
policies, programs and partnerships. For more information about our
operations in Canada, visit www.merck.ca.
Forward Looking Statement
This news release includes "forward-looking statements" within the
meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. Such statements may include,
but are not limited to, statements about the benefits of the merger
between Merck and Schering-Plough, including future financial and
operating results, the combined company's plans, objectives,
expectations and intentions and other statements that are not
historical facts. Such statements are based upon the current beliefs
and expectations of Merck's management and are subject to significant
risks and uncertainties. Actual results may differ from those set forth
in the forward-looking statements. The following factors, among others,
could cause actual results to differ from those set forth in the
forward-looking statements: the possibility that the expected synergies
from the merger of Merck and Schering-Plough will not be realized, or
will not be realized within the expected time period; the impact of
pharmaceutical industry regulation and health care legislation; the
risk that the businesses will not be integrated successfully;
disruption from the merger making it more difficult to maintain
business and operational relationships; Merck's ability to accurately
predict future market conditions; dependence on the effectiveness of
Merck's patents and other protections for innovative products; the risk
of new and changing regulation and health policies in the United States
and internationally and the exposure to litigation and/or regulatory
actions. Merck undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause results
to differ materially from those described in the forward-looking
statements can be found in Merck's 2009 Annual Report on Form 10-K and
the company's other filings with the Securities and Exchange Commission
(SEC) available at the SEC's Internet site (www.sec.gov).
NOTE TO EDITORS:
B-ROLL AVAILABLE TODAY (APRIL 26, 2011) IN ENGLISH AND FRENCH BETWEEN
10:00 AND 11:00 AM EDT AND BETWEEN 12:00 AND 12:30 PM EDT IN ENGLISH
Anik F2C 3B
Downlink Freq: 3820 V
Audios 6.2 and 6.8
1 GARDASIL® Product Monograph approved on April 14, 2011, page 18.
2 GARDASIL® Product Monograph approved on April 14, 2011, page 18.
3 Burchell A.N., Tellier P-P., et al. Influence of Partner's Infection
status on Prevalent Human Papillomavirus Among Persons With a New Sex
Partner. Sexually Transmitted Diseases 2009; 36(12): Epub 2009 Aug 21.
4 GARDASIL® Product Monograph approved on April 14, 2011, page 56.
5 GARDASIL® Product Monograph approved on April 14, 2011, page 19.
6 GARDASIL® Product Monograph approved on April 14, 2011, page 18.
7 GARDASIL® Product Monograph approved on April 14, 2011, page 18.
For further information:
| Sheila Murphy |
| || Roch Landriault / Stephanie Lyttle |
NATIONAL Public Relations
514-843-2345 / 514-843-2365